Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.177 (
BIS
)
957
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In critically ill patients, the central nervous system remains vulnerable to multiple insults including ischemia, hemorrhagic events, and encephalopathy. The peripheral nervous system is vulnerable in the setting of neuro-muscular blockade (NMB), related drug-drug interactions, and drug-clinical state interactions. Optimal assessment of the nervous system is done by means of the clinical neurological examination. In this manner, orientation, arousal, and responsiveness to stimulation provide feedback on focal and global stability of the central nervous system. Where clinical evaluation is compromised, such as with deep sedation and NMB, risk of undetected seizure activity, and/or progression of neurological injury increases dramatically. A patient receiving NMB risks breakthrough awareness and pain. Long-term complications of NMB including prolonged
weakness
or paralysis as well as post-traumatic stress dramatically increase morbidity and length of stay. Technologies such as electroencephalogram (EEG) and bispectral index (
BIS
trade mark ) monitoring are effective for assessing cerebral function as well as level of sedation or arousal, respectively, in patients with a compromised neurological assessment. Neuromuscular transmission (NMT) monitoring by means of peripheral nerve stimulation and assessment of the evoked response may be utilized, within the context of clinical assessment, to determine level of chemical paralysis and minimize dosing of NMB agents. This article explores utilization and differentiates technologies such as EEG,
BIS
, and NMT monitoring. Monitoring parameters are illustrated using a case study approach.
...
PMID:Continuous nervous system monitoring, EEG, the bispectral index, and neuromuscular transmission. 1281 56
A 34-year-old man with adrenoleukodystrophy (ALD) was scheduled for pump system insertion of intrathecal baclofen therapy under general anesthesia. ALD, a rare genetic disorder, is associated with a total body increase in long chain fatty acids caused by defective degradation, and includes various nervous system abnormalities, muscular
weakness
, in addition to adrenal insufficiency. He had contracture of the both legs, and muscular
weakness
of the left hand, and Mallampati class III, but no respiratory disability. In the operating room, we administered hydrocortisone 100 mg for steroid coverage, and low-dose midazolam, and fentanyl. As spontaneous breathing remained, we could easily see epiglottis and arytenoid cartilage by McGRATH. Therefore we selected rapid-induction of anesthesia with thiamylal, and rocuronium 40 mg, under cricoid pressure. We avoided propofol. Anesthsia was maintained with sevoflurane and remifentanil, monitoring
BIS
and train of four. No more rocuronium was administered, and anesthesia was uneventful. Intrathecal baclofen therapy is given to patients who have severe contracture. When we selected general anesthesia, we should be aware of the possibility of muscular
weakness
, and cannot intubate cannot ventilate scenario.
...
PMID:[Anesthetic Management of an Adrenoleukodystrophy Patient for Intrathecal Baclofen Therapy]. 2718 15